| Name | Title | Contact Details |
|---|
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera`s European operations are conducted from London by its subsidiary, Alimera Sciences Limited.
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
hope pharma inc is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PharmaMed Resources is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.